Zinc and thymic hormone-dependent immunity in normal ageing and in patients with senile dementia of the Alzheimer type.
Level 4 - case-series / case-control
Cross-sectional comparative case-control study assessing biomarker levels across patient and control groups.
PubMed 2332483 · doi:10.1016/0165-5728(90)90070-4
What was done
The authors compared plasma zinc levels, active and inactive thymulin levels, and in vitro thymulin reactivation after zinc addition across young controls, aged controls, patients with dementia of the Alzheimer type, and patients with non-Alzheimer type dementia. Mitogen-stimulated lymphocyte proliferation and interleukin-2-induced cell activation were also measured.
What was found
The abstract reports no numerical values, confidence intervals, or test statistics. Directionally, plasma zinc and basal active thymulin decreased with age, with zinc levels not differing between dementia patients and aged controls. In vitro thymulin reactivation after zinc addition was decreased in aged controls and was further impaired in dementia patients. Mitogen-induced lymphocyte proliferation and interleukin-2-induced activation declined with age, with no difference between aged controls and Alzheimer-type dementia patients.
Why it matters
The study indicates that thymic hormone bioavailability or activation is impaired in dementia beyond normal aging alterations, independent of circulating total zinc levels.
Limits
Sample sizes, participant demographics, exact diagnostic criteria, and numerical data with variance metrics are completely absent from the abstract. The cross-sectional design cannot establish causality or determine whether thymulin reactivation deficits are a cause or consequence of neurodegeneration.
Cited by
- supports Thymulin is a zinc-dependent nine-amino-acid peptide secreted by the thymus whose levels decline with age.